Lynparza (olaparib)

About Lynparza (Olaparib) in Ovarian Cancer

LYNPARZA (olaparib tablets) is the only PARP inhibitor (PARPi) approved as first-line maintenance therapy in newly diagnosed women with BRCA mutated advanced ovarian cancer1

  • LYNPARZA tablet formulation is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following completion of first-line platinum-based chemotherapy.1
  • LYNPARZA tablet formulation is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1

Lynparza is also indicated in BRCA mutated, HER2 negative locally advanced or metastatic breast cancer. For more information, please refer to the summary of product characteristics.

Lynparza maintenance therapy is available for reimbursement within both the newly diagnosed, and platinum-sensitive relapsed setting, depending on your patient’s needs (all recommendations are subject to eligibility criteria):

In England

  • LYNPARZA (tablets) is recommended by NICE for use via the Cancer Drugs Fund (CDF) as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based first-line chemotherapy and who have a deleterious or suspected deleterious germline and/or somatic BRCA mutation (subject to eligibility criteria)2
  • LYNPARZA (tablets) is recommended by NICE as an option for treating adults with platinum-sensitive relapsed ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum-based chemotherapy AND only if they have had 3 or more courses of platinum-based chemotherapy3
  • Lynparza is also indicated in BRCA mutated, HER2 negative locally advanced or metastatic breast cancer. For more information, please refer to the summary of product characteristics.1

Lynparza is also indicated in BRCA mutated, HER2 negative locally advanced or metastatic breast cancer. For more information, please refer to the summary of product characteristics.1

In Scotland

  • LYNPARZA (tablets) is recommended by the SMC as an option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy4
  • LYNPARZA (capsules) is recommended by the SMC as an option for the treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 (germline and/or somatic) mutations and whose disease has responded to platinum-based chemotherapy5

Summary of LYNPARZA tablets licences, indications and reimbursement status in ovarian cancer1–6

LYNPARZA tablets (100 mg and 150 mg) should not be substituted for LYNPARZA capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation; therefore, the specific dose recommendations for each formulation should be followed.1

BRCA testing website
To learn about and access the BRCAct tumour testing service, please click here

LYNPARZA capsule formulation is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.6

For women with advanced BRCAm ovarian cancer choose LYNPARZA tablets as standard of care at the earliest opportunity for maintenance treatment1,7,8

At 3 years, 70% of newly diagnosed advanced ovarian cancer patients will have had disease progression7

There is an urgent need for improvement in the current outcomes for newly diagnosed advanced ovarian cancer9–12